高级检索
当前位置: 首页 > 详情页

Traditional Herbal Medicine: A Potential Therapeutic Approach for Adjuvant Treatment of Non-small Cell Lung Cancer in the Future

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Macau University of Science and Technology, Taipa, Macau, China. [2]Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. [3]Southern Medical University, Guangzhou, Guangdong, China. [4]Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Guangzhou, Guangdong, China. [5]Guangdong Provincial Engineering Laboratory of Chinese Medicine Preparation Technology, Guangzhou, Guangdong, China.
出处:
ISSN:

摘要:
Lung carcinoma is the primary reason for cancer-associated mortality, and it exhibits the highest mortality and incidence in developed and developing countries. Non-small cell lung cancer (NSCLC) and SCLC are the 2 main types of lung cancer, with NSCLC contributing to 85% of all lung carcinoma cases. Conventional treatment mainly involves surgery, chemoradiotherapy, and immunotherapy, but has a dismal prognosis for many patients. Therefore, identifying an effective adjuvant therapy is urgent. Historically, traditional herbal medicine has been an essential part of complementary and alternative medicine, due to its numerous targets, few side effects and substantial therapeutic benefits. In China and other East Asian countries, traditional herbal medicine is increasingly popular, and is highly accepted by patients as a clinical adjuvant therapy. Numerous studies have reported that herbal extracts and prescription medications are effective at combating tumors. It emphasizes that, by mainly regulating the P13K/AKT signaling pathway, the Wnt signaling pathway, and the NF-κB signaling pathway, herbal medicine induces apoptosis and inhibits the proliferation and migration of tumor cells. The present review discusses the anti-NSCLC mechanisms of herbal medicines and provides options for future adjuvant therapy in patients with NSCLC.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 全科医学与补充医学 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 全科医学与补充医学 4 区 肿瘤学
JCR分区:
出版当年[2020]版:
Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Q3 ONCOLOGY
最新[2023]版:
Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Macau University of Science and Technology, Taipa, Macau, China.
共同第一作者:
通讯作者:
通讯机构: [1]Macau University of Science and Technology, Taipa, Macau, China. [3]Southern Medical University, Guangzhou, Guangdong, China. [4]Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Guangzhou, Guangdong, China. [5]Guangdong Provincial Engineering Laboratory of Chinese Medicine Preparation Technology, Guangzhou, Guangdong, China. [*1]Faculty of Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau 90000, China [*2]School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号